期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 4, 页码 2024-2045出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c01360
关键词
-
资金
- NIH [F30GM113299]
- Breast Cancer Research Foundation
A new class of metal ion chelators was identified to reactivate mutant p53 by shuttling zinc into cells, demonstrating similar efficacy to traditional TSCs. These chelators showed reduced toxicity and equivalent growth inhibition in rodents, with C85 functioning as a chemotherapy and radiation sensitizer. This study indicates the potential of benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones as zinc metallochaperones in restoring mutant p53.
We identified a set of thiosemicarbazone (TSC) metal ion chelators that reactivate specific zinc-deficient p53 mutants using a mechanism called zinc metallochaperones (ZMCs) that restore zinc binding by shuttling zinc into cells. We defined biophysical and cellular assays necessary for structure-activity relationship studies using this mechanism. We investigated an alternative class of zinc scaffolds that differ from TSCs by substitution of the thiocarbamoyl moiety with benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones. Members of this series bound zinc with similar affinity and functioned to reactivate mutant p53 comparable to the TSCs. Acute toxicity and efficacy assays in rodents demonstrated C1 to be significantly less toxic than the TSCs while demonstrating equivalent growth inhibition. We identified C85 as a ZMC with diminished copper binding that functions as a chemotherapy and radiation sensitizer. We conclude that the benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones can function as ZMCs to reactivate mutant p53 in vitro and in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据